Long-term testosterone replacement therapy (TRT) is associated with an increased risk of cardiovascular events (CVE) and death among HIV-positive men, authors of a retrospective chart review reported at IDWeek 2015.
Patients with HIV and tuberculosis (TB) coinfection are discontinuing first-line antitubercular therapy (ATT) at disturbingly high rates because of side effects like skin reactions, gastrointestinal symptoms, and hepatotoxicity, according to study findings reported at IDWeek 2015.
Among HIV-positive patients, hepatitis C virus (HCV) coinfection, low baseline CD4 counts and other factors increase the risk of tenofovir-associated renal failure, reported authors of a retrospective cohort study presented at IDWeek 2015.
Administering diuretics does not increase acute kidney injury (AKI) risk among HIV-positive patients who are taking tenofovir disoproxil fumarate (TDF), and controlling blood pressure may be a more important consideration when it comes to preventing AKI, suggests a retrospective analysis reported at IDWeek 2015.
Statins are associated with decreased progression of liver disease among patients who are coinfected with HIV and hepatitis C virus (HCV), according findings from a single-institution cohort study reported at IDWeek 2015.
Including tenofovir alafenamide (TAF) in single-tablet elvitegravir/cobicistat/emtricitabine (E/C/F/TAF) is associated with reduced renal and bone toxicity compared to tenofovir disoproxil fumarate (TDF)-containing single-tablet (E/C/F/TDF) therapy, according to an analysis of data from two Phase 3 trials, reported at IDWeek 2015.
Researchers at IDWeek 2015 presented positive efficacy data for the grazoprevir/elbasvir (EBR/GZR) regimen for patients co-infected with hepatitis C virus (HCV) and HIV.
Once-daily single-tablet ledipasvir/sofosbuvir (LDV/SOF) provided high rates of sustained virologic response (SVR) at Week 12 in both patients with hepatitis C virus (HCV) mono-infection and HIV/HCV coinfection, according to results of a pooled analysis presented at IDWeek 2015.
Treatment with boceprevir and pegylated interferon/ribavirin (PIFN/R) in persons co-infected with hepatitis C virus (HCV)and HIV resulted in higher sustained virologic response (SVR) rates at 12 weeks if they were treatment-naïve without cirrhosis, Phase 3 trial results reported at IDWeek 2015 have found.
The combination of either atazanavir plus cobicistat (ATV+c) or atazanavir plus ritonavir (ATV+r) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is an effective treatment option for patients who are infected with HIV regardless of race, sex, and age, with high and similar virologic success rates, a Week 48 subgroup analysis of a randomized Phase 3 trial confirmed at IDWeek 2015.
Please login or register first to view this content.
